Recent Updates — GOVXW
GeoVax Labs Inc. received a Staff Determination Letter from Nasdaq notifying the company of its intent to delist common stock due to failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days ending August 26, 2026. The company also failed to meet the $2,500,000 stockholders’ equity requirement. Because GeoVax executed a 1-for-25 reverse stock split on January 12, 2026, it is ineligible for the standard 180-day compliance period. Trading may be suspended starting September 8, 2026, if no hearing request is filed; however, the company plans to appeal before the September 3 deadline, which will stay further actions and allow continued trading during the process. GeoVax Labs Inc. operates in the biotechnology industry, focusing on vaccine development.
GeoVax Labs Inc. entered into a warrant exercise inducement offer on August 25, 2026, with an existing institutional investor to exercise outstanding warrants for gross cash proceeds of approximately $3,646,482. In exchange, the company issued new unregistered warrants to purchase up to 11,395,256 shares at an exercise price of $0.64 per share. The transaction closed on August 26, 2026, with proceeds designated for working capital and general corporate purposes. GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies.
GeoVax Labs reported a net loss of $4.4 million ($0.97 per share) for the second quarter of 2026, compared to a net loss of $5.4 million for the same period in 2025. The company reported zero revenue for the quarter, following the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program. GeoVax is now prioritizing its GEO-MVA vaccine for mpox and smallpox, with a pivotal immunobridging study planned for the fourth quarter of 2026, and its Gedeptin immuno-oncology program. As of June 30, 2026, the company held $3.1 million in cash. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumors.